Jupiter Neurosciences (NASDAQ: JUNS) to appeal Nasdaq delisting
Rhea-AI Filing Summary
JUPITER NEUROSCIENCES, INC. (JUNS) disclosed that Nasdaq’s Listing Qualifications Staff has determined to delist the company’s common stock from the Nasdaq Capital Market because the market value of listed securities remained below the required $35,000,000 under Nasdaq Listing Rule 5550(b)(2) after a 180-day compliance period.
The company plans to timely appeal this determination and request a hearing before a Nasdaq Hearings Panel, which it expects will stay further action while the appeal is pending, but there is no assurance of success or of regaining compliance with Nasdaq’s continued listing requirements.
Separately, the company was informed that its stock maintained a closing bid price of at least $1.00 for 10 consecutive business days from August 13–26, 2026, regaining compliance with Nasdaq Listing Rule 5550(a)(2) on minimum bid price, though future compliance is not assured.
Positive
- Regained compliance with $1.00 minimum bid price under Nasdaq Listing Rule 5550(a)(2) after maintaining at least a $1.00 closing bid for 10 consecutive business days from August 13–26, 2026.
Negative
- Nasdaq Staff has determined to delist JUNS from the Nasdaq Capital Market for failure to meet the $35,000,000 market value of listed securities requirement under Nasdaq Listing Rule 5550(b)(2) after a 180-day grace period.
- Ongoing listing uncertainty as the company will appeal to a Nasdaq Hearings Panel, with no assurance the appeal will succeed or that continued listing or compliance with all Nasdaq requirements will be achieved.
8-K Event Classification
3 items: 3.01, 8.01, 9.01
3 items
Item 3.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Securities
The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Required market value of listed securities: $35,000,000
Compliance period length: 180 calendar days
Minimum bid price: $1.00 per share
+3 more
6 metrics
Required market value of listed securities
$35,000,000
Minimum market value required for continued listing under Nasdaq Listing Rule 5550(b)(2)
Compliance period length
180 calendar days
Period ending August 25, 2026 provided to regain compliance with Nasdaq Listing Rule 5550(b)(2)
Minimum bid price
$1.00 per share
Threshold under Nasdaq Listing Rule 5550(a)(2) that JUNS met for 10 consecutive business days
Consecutive business days at or above $1.00 bid
10 business days
From August 13, 2026 through August 26, 2026, restoring compliance with the minimum bid price rule
Initial notice date for market value deficiency
February 26, 2026
Date Nasdaq Staff notified JUNS its market value of listed securities was below the $35,000,000 requirement
Compliance end date for market value rule
August 25, 2026
End of the 180-day period to regain compliance with Nasdaq Listing Rule 5550(b)(2)
Key Terms
Nasdaq Listing Rule 5550(b)(2), Nasdaq Listing Rule 5550(a)(2), continued listing requirements, Nasdaq Hearings Panel, +1 more
5 terms
Nasdaq Listing Rule 5550(b)(2) regulatory
"required for continued listing under Nasdaq Listing Rule 5550(b)(2)"
Nasdaq Listing Rule 5550(a)(2) regulatory
"minimum bid price requirement for continued listing on The Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(a)(2)"
continued listing requirements regulatory
"regain compliance with Nasdaq’s continued listing requirements"
Rules a stock exchange sets that a publicly traded company must keep meeting to stay listed and tradable on that exchange, such as minimum share price, market value, timely financial reports, and basic governance practices. Like a club’s membership rules, they matter because falling short can lead to warnings, penalties or removal from the exchange, which can cut liquidity, hurt share value and increase the risk for investors.
Nasdaq Hearings Panel regulatory
"requesting a hearing before the Nasdaq Hearings Panel"
A Nasdaq hearings panel is a group of experts that reviews cases when a company's stock listing is at risk of being removed from the exchange. They evaluate whether the company has met certain standards and determine if it can keep trading on Nasdaq. This process matters to investors because it can affect a company's ability to raise money and maintain credibility in the market.
forward-looking statements regulatory
"Certain information contained in this report consists of forward-looking statements"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
FAQ
Why is JUNS facing potential delisting from Nasdaq?
Nasdaq’s Listing Qualifications Staff determined to delist JUPITER NEUROSCIENCES, INC. (JUNS) because the market value of its listed securities stayed below the required $35,000,000 under Nasdaq Listing Rule 5550(b)(2) throughout a 180-day compliance period ending August 25, 2026.
What compliance deadline did JUNS miss for Nasdaq’s market value rule?
JUNS was given 180 calendar days, until August 25, 2026, to regain compliance with the $35,000,000 market value of listed securities requirement under Nasdaq Listing Rule 5550(b)(2), but did not regain compliance by that date.
Has JUNS regained compliance with Nasdaq’s minimum bid price rule?
Yes. Nasdaq Staff notified JUNS that for the 10 consecutive business days from August 13–26, 2026, its closing bid price was at least $1.00 per share, restoring compliance with Nasdaq Listing Rule 5550(a)(2) on minimum bid price.
What steps is JUNS taking to address the Nasdaq delisting determination?
JUNS intends to appeal the Staff’s delisting determination by requesting a hearing before a Nasdaq Hearings Panel. The company expects the hearing request will stay further action pending a final decision, but there is no assurance of a favorable outcome.
Does JUNS guarantee it will remain listed on Nasdaq after the appeal?
No. The company states there can be no assurance that the Panel will grant continued listing, that any relief from delisting will be provided, or that the company will regain and maintain compliance with Nasdaq’s continued listing requirements.
Which Nasdaq listing rules are currently relevant to JUNS?
JUNS is affected by Nasdaq Listing Rule 5550(b)(2) regarding a $35,000,000 market value of listed securities, with a Staff determination to delist, and Nasdaq Listing Rule 5550(a)(2), where it has regained compliance with the $1.00 minimum bid price requirement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
